CASI(Delisted)
CASI Pharmaceuticals·NASDAQ
--
--(--)
CASI Pharmaceuticals (CASI) Financials Overview
CASI Pharmaceuticals (CASI) released its earnings on Nov 14, 2025: revenue was 3.08M (YoY -60.54%), beat estimates; EPS was -0.68 (YoY -23.64%), missed estimates.
Revenue / YoY
3.08M
-60.54%
EPS / YoY
-0.68
-23.64%
Report date
Nov 14, 2025
EPS
Revenue
Revenue & Expenses
CASI has released its 2025 Q3 earnings report, with revenue of 3.08M, reflecting a YoY change of -60.54%, and net profit of -10.88M, showing a YoY change of -29.64%. The Sankey diagram below clearly presents CASI's revenue sources and cost distribution.
Key Indicators
CASI Pharmaceuticals (CASI) key financial stats and ratios, covering profitability, financial health, and leverage.
CASI Pharmaceuticals (CASI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
CASI Pharmaceuticals (CASI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
CASI Pharmaceuticals (CASI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does CASI Pharmaceuticals (CASI) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track CASI Pharmaceuticals (CASI) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
More Financial Metrics
You can ask Aime
No Data
